Tau time for Alzheimer’s. Plus: FDA delays, Merck’s $4B deal, HK IPOs

On BioCentury’s latest podcast: Why tau may be approaching a tipping point for Alzheimer’s drug development

Belief in tau — both as a target and surrogate endpoint — for Alzheimer’s disease is building among leaders in the field, and they aren’t letting a series of setbacks in the clinic deter them. On the latest BioCentury This Week podcast, Executive Editor Selina Koch discusses how tau could be reaching a tipping point, explaining how tau stands apart from amyloid in important ways and how companies pursuing the protein benefit from the lessons learned from decades of designing clinical trials for the indication.

Also on this week’s episode, Washington Editor Steve Usdin details how political moves have begun to intrude into the Trump administration’s regulation of vaccines, a topic that’s also taken up by Phil Krause and Luciana Borio in a BioCentury Guest Commentary published Monday.

BioCentury’s editors then discuss delays for drug regulation at FDA, the $3.9 billion deal by  Merck KGaA (Xetra:MRK) to acquire Springworks Therapeutics Inc. (NASDAQ:SWTX), and why biotech IPOs could soon have a moment in Hong Kong.

This episode of BioCentury This Week podcast is sponsored by RemeGen.